FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308325201> ?p ?o ?g. }

• W4308325201 endingPage "7" @default.
• W4308325201 startingPage "1" @default.
• W4308325201 abstract "A recently published manuscript described findings from a phase 2 open label study of the microbiota-based live biotherapeutic product RBX2660 in patients with two or more previous recurrent Clostridioides difficile infection (rCDI) episodes, and described long-term safety and sustained treatment success through 24 months. As previous studies have typically focused on short-term clinical outcomes, these new data provide insight into the tolerability, safety, and efficacy of RBX2660 over the long term. When microbiota-based products were first evaluated, the long-term efficacy and safety were principal concerns of the United States Food and Drug Administration. Microbiota-based live biotherapeutic products (LBPs) represent an emerging approach to the management of CDI and perhaps other gastrointestinal and medical conditions whose pathogenesis is defined by microbial dysbiosis. RBX2660 is a human-derived, broad consortium microbiota-based LBP that consists of a population of microbes obtained from healthy stool donors and may reflect the symbiotic nature of a healthy colonic microbiome. RBX2660 is rectally administered and does not require sedation or special preparation of the recipient. Potential advantages of the rectal administration of RBX2660 include the ease of administration and lack of need for any bowel preparation, which may benefit those who are frail, have swallowing issues, or cannot take bowel laxative preparations. In this multicenter prospective trial of rCDI, patients who achieved treatment success 8 weeks after receiving RBX2660 continued to have a sustained clinical response over the course of long-term follow-up, with more than 90% of treatment responders remaining CDI-free at 6, 12, and 24 months. Following receipt of RBX2660, the gut microbiota of those with treatment success were restored from a dysbiotic state to become more diverse and similar to RBX2660 composition. The restoration of the microbiota occurred as early as 7 days after RBX2660 administration and remained stable through the 24-month analysis. No new adverse outcomes were observed during the prospective assessment, and the safety profile of RBX2660 was consistent with previous studies. Based on the clinical studies, RBX2660 will most likely benefit those with ≥ 1 rCDI episode or those who are at a high risk of subsequent rCDI, such as patients who have comorbid conditions including renal disease, heart disease, or inflammatory bowel disease, or who are immunosuppressed. The role of microbiome-based therapeutics in 47 Clostridioides difficile infection: Durable, long-term results of RBX2660 (MP4 511833 KB)." @default.
• W4308325201 created "2022-11-11" @default.
• W4308325201 creator A5089617870 @default.
• W4308325201 date "2022-11-07" @default.
• W4308325201 modified "2023-10-18" @default.
• W4308325201 title "The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660" @default.
• W4308325201 cites W2065777365 @default.
• W4308325201 cites W2071054182 @default.
• W4308325201 cites W2144282350 @default.
• W4308325201 cites W2148171446 @default.
• W4308325201 cites W2174455357 @default.
• W4308325201 cites W2182683962 @default.
• W4308325201 cites W2283572643 @default.
• W4308325201 cites W2582069104 @default.
• W4308325201 cites W2582743482 @default.
• W4308325201 cites W2616825195 @default.
• W4308325201 cites W2618318010 @default.
• W4308325201 cites W2772501635 @default.
• W4308325201 cites W2791326569 @default.
• W4308325201 cites W2792237904 @default.
• W4308325201 cites W2795021885 @default.
• W4308325201 cites W2888284714 @default.
• W4308325201 cites W2889311756 @default.
• W4308325201 cites W2971563172 @default.
• W4308325201 cites W3004863303 @default.
• W4308325201 cites W3012186458 @default.
• W4308325201 cites W3014714752 @default.
• W4308325201 cites W3117645128 @default.
• W4308325201 cites W3120114463 @default.
• W4308325201 cites W3120944707 @default.
• W4308325201 cites W3129422799 @default.
• W4308325201 cites W3160125504 @default.
• W4308325201 cites W3184742238 @default.
• W4308325201 cites W3207309052 @default.
• W4308325201 cites W3207355328 @default.
• W4308325201 cites W3209596191 @default.
• W4308325201 cites W4200205422 @default.
• W4308325201 cites W4220914817 @default.
• W4308325201 cites W4226296560 @default.
• W4308325201 cites W4226353132 @default.
• W4308325201 doi "https://doi.org/10.1007/s40121-022-00714-9" @default.
• W4308325201 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36342653" @default.
• W4308325201 hasPublicationYear "2022" @default.
• W4308325201 type Work @default.
• W4308325201 citedByCount "4" @default.
• W4308325201 countsByYear W43083252012023 @default.
• W4308325201 crossrefType "journal-article" @default.
• W4308325201 hasAuthorship W4308325201A5089617870 @default.
• W4308325201 hasBestOaLocation W43083252011 @default.
• W4308325201 hasConcept C126322002 @default.
• W4308325201 hasConcept C143121216 @default.
• W4308325201 hasConcept C177713679 @default.
• W4308325201 hasConcept C197934379 @default.
• W4308325201 hasConcept C203014093 @default.
• W4308325201 hasConcept C2777165150 @default.
• W4308325201 hasConcept C2778375690 @default.
• W4308325201 hasConcept C2908647359 @default.
• W4308325201 hasConcept C2910067853 @default.
• W4308325201 hasConcept C3018890749 @default.
• W4308325201 hasConcept C535046627 @default.
• W4308325201 hasConcept C539455810 @default.
• W4308325201 hasConcept C60644358 @default.
• W4308325201 hasConcept C71924100 @default.
• W4308325201 hasConcept C86803240 @default.
• W4308325201 hasConcept C98274493 @default.
• W4308325201 hasConcept C99454951 @default.
• W4308325201 hasConceptScore W4308325201C126322002 @default.
• W4308325201 hasConceptScore W4308325201C143121216 @default.
• W4308325201 hasConceptScore W4308325201C177713679 @default.
• W4308325201 hasConceptScore W4308325201C197934379 @default.
• W4308325201 hasConceptScore W4308325201C203014093 @default.
• W4308325201 hasConceptScore W4308325201C2777165150 @default.
• W4308325201 hasConceptScore W4308325201C2778375690 @default.
• W4308325201 hasConceptScore W4308325201C2908647359 @default.
• W4308325201 hasConceptScore W4308325201C2910067853 @default.
• W4308325201 hasConceptScore W4308325201C3018890749 @default.
• W4308325201 hasConceptScore W4308325201C535046627 @default.
• W4308325201 hasConceptScore W4308325201C539455810 @default.
• W4308325201 hasConceptScore W4308325201C60644358 @default.
• W4308325201 hasConceptScore W4308325201C71924100 @default.
• W4308325201 hasConceptScore W4308325201C86803240 @default.
• W4308325201 hasConceptScore W4308325201C98274493 @default.
• W4308325201 hasConceptScore W4308325201C99454951 @default.
• W4308325201 hasFunder F4320322992 @default.
• W4308325201 hasIssue "1" @default.
• W4308325201 hasLocation W43083252011 @default.
• W4308325201 hasLocation W43083252012 @default.
• W4308325201 hasLocation W43083252013 @default.
• W4308325201 hasOpenAccess W4308325201 @default.
• W4308325201 hasPrimaryLocation W43083252011 @default.
• W4308325201 hasRelatedWork W2087016115 @default.
• W4308325201 hasRelatedWork W2107697672 @default.
• W4308325201 hasRelatedWork W2349164817 @default.
• W4308325201 hasRelatedWork W2911190614 @default.
• W4308325201 hasRelatedWork W3014585000 @default.
• W4308325201 hasRelatedWork W3130658993 @default.
• W4308325201 hasRelatedWork W3189197085 @default.
• W4308325201 hasRelatedWork W4296655839 @default.

• next